Characteristics Overall (n = 201) ≤14 days (n = 71) 15-42 days (n = 86) ≥43 days (n = 44) p-value Age at diagnosis (mean±SD) 48⋅89±9⋅86 49⋅17±8⋅16 48⋅4±10⋅54 49⋅39±11⋅13 0⋅827… Click to show full abstract
Characteristics Overall (n = 201) ≤14 days (n = 71) 15-42 days (n = 86) ≥43 days (n = 44) p-value Age at diagnosis (mean±SD) 48⋅89±9⋅86 49⋅17±8⋅16 48⋅4±10⋅54 49⋅39±11⋅13 0⋅827 Tumor size (mm, mean±SD) 25⋅53±15⋅24 26⋅87±14⋅06 24⋅47±16⋅59 25⋅16±15⋅24 0⋅635 Setting 0⋅812 City of the hospital 97 (48⋅3%) 37 (52⋅1%) 42 (48⋅8%) 18 (40⋅9%) Other cities in the same province 87 (43⋅3%) 29 (40⋅8%) 36 (41⋅9%) 22 (50⋅0%) Other provinces 17 (8⋅5%) 5 (7⋅0%) 8 (9⋅3%) 4 (9⋅1%) Insurance type 0⋅680 Private 30 (14⋅9%) 13 (18⋅3%) 13 (15⋅1%) 4 (9⋅1%) Governmental 152 (75⋅6%) 52 (73⋅2%) 65 (75⋅6%) 35 (79⋅5%) Uninsured 16 (8⋅0%) 4 (5⋅6%) 7 (8⋅1%) 5 (11⋅4%) Others 3 (1⋅5%) 2 (2⋅8%) 1 (1⋅2%) 0 (0⋅0%) Degree level 0⋅505 Junior high school or lower 89 (44⋅3%) 28 (39⋅4%) 39 (45⋅3%) 22 (50⋅0%) High school or college 77 (38⋅3%) 28 (39⋅4%) 31 (36⋅0%) 18 (40⋅9%) Bachelor degree or above 35 (17⋅4%) 15 (21⋅1%) 16 (18⋅6%) 4 (9⋅1%) Marital Status 0⋅148 Married 187 (93⋅0%) 69 (97⋅2%) 77 (89⋅5%) 41 (93⋅2%) Unmarrieda 14 (7⋅0%) 2 (2⋅8%) 9 (10⋅5%) 3 (6⋅8%) Method of detection 0⋅281 Symptom-detected 178 (88⋅6%) 64 (90⋅1%) 78 (90⋅7%) 36 (81⋅8%) Screen-detected 23 (11⋅4%) 7 (9⋅9%) 8 (9⋅3%) 8 (18⋅2%) Menstrual status 0⋅490 Premenopausal 102 (50⋅7%) 32 (45⋅1%) 46 (53⋅5%) 24 (54⋅5%) Menopausal 99 (49⋅3%) 39 (54⋅9%) 40 (46⋅5%) 20 (45⋅5%) Neoadjuvant therapy <0⋅001 Yes 41 (20⋅4%) 3 (4⋅2%) 23 (26⋅7%) 15 (34⋅1%) No 160 (79⋅6%) 68 (95⋅8%) 63 (73⋅3%) 29 (65⋅9%) Excision biopsy before surgery 0⋅001 Yes 16 (8⋅0%) 0 (0⋅0%) 11 (12⋅8%) 5 (11⋅4%) No 185 (92⋅0%) 71 (100⋅0%) 75 (87⋅2%) 39 (88⋅6%) Type of surgery 0⋅072 Mastectomy 168 (83⋅6%) 60 (84⋅5%) 76 (88⋅4%) 32 (72⋅7%) Lumpectomy 33 (16⋅4%) 11 (15⋅5%) 10 (11⋅6%) 12 (27⋅3%) Reconstruction after mastectomy 0⋅822 Yes 11 (5⋅5%) 3 (4⋅2%) 5 (5⋅8%) 3 (6⋅8%) No 190 (94⋅5%) 68 (95⋅8%) 81 (94⋅2%) 41 (93⋅2%) is the largest medical centre in Western China. It is located in Chengdu, Sichuan, where the pandemic was the most severe from February to April. We retrospectively summarised the time-tosurgery (TTS) and patient characteristics of 201 consecutive breast cancer patients who received surgeries between 15 February and 30 April 2020. The median TTS was 16 days (range 2-160 days). The TTS for patients who were diagnosed before 24 Jan 2020 were longer than those diagnosed after the COVID-19 outbreak and at pandemic mitigation (58⋅42± 25⋅15 days vs. 19⋅06± 11⋅59 days, p < 0⋅001). In early February, transportation between cities and provinces were temporarily cut off to stop the virus from spreading. Despite the traffic barriers, the patients who resided at areas with different distances toward the hospital did not suffer from different TTS (p = 0⋅812, Table 1). The patients who lost access to the original hospital may have been treated at the local hospitals. In order to minimize
               
Click one of the above tabs to view related content.